Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mucosis, a Dutch biotechnology company, has commenced the Phase 1 clinical study of influenza vaccine FluGEM, based on Mimopath, a proprietary platform technology for developing potent vaccines.
Subscribe to our email newsletter
The Mimopath technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry.
Mucosis has developed a technique to formulate the L lactis bacteria into non-living bacterial-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin.
The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle.
The vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
The clinical study will be conducted in conjunction with the Centre for Human Drug Research, the Netherlands.